Moleculin Biotech - MBRX

Moleculin Biotech - MBRX Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers and viruses.

We are heading to the ESC Cardio-Oncology 2026 Conference, taking place June 19–20 in Vienna.Excited to join experts foc...
06/15/2026

We are heading to the ESC Cardio-Oncology 2026 Conference, taking place June 19–20 in Vienna.

Excited to join experts focused on improving outcomes where heart health and cancer care meet.

We’re at , June 11-14 in Stockholm, Sweden.Stop by booth .06B to learn about Annamycin, our lead program currently bei...
06/12/2026

We’re at , June 11-14 in Stockholm, Sweden.

Stop by booth .06B to learn about Annamycin, our lead program currently being evaluated in the pivotal Phase 3 MIRACLE trial for R/R AML.

Reach out to [email protected] to connect.

Moleculin will be attending the EHA2026 Congress, June 11–14 in Stockholm. We look forward to engaging with the global h...
06/08/2026

Moleculin will be attending the EHA2026 Congress, June 11–14 in Stockholm.

We look forward to engaging with the global hematology community and sharing our commitment to advancing innovative cancer therapies.

06/05/2026

"We believe the findings provide important third-party validation of both the clinical and commercial potential of Annamycin," said Walter Klemp, Moleculin CEO. Read more on the findings, including a parallel survey of payers showing strong support for Annamycin filling a significant unmet need. https://bit.ly/4uhLqFg

06/05/2026

In a recent independent market landscape assessment, surveyed oncologists reported high likelihood to prescribe Annamycin (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers. Read more about the assessment: https://bit.ly/4uhLqFg

06/05/2026

"These independent research findings are highly encouraging and reinforce the potential role we believe Annamycin can play in addressing one of the most difficult areas of AML treatment," said Walter Klemp, Chairman and CEO. Read more about the recent results from an independent market landscape assessment evaluating Annamycin in R/R AML: https://bit.ly/4uhLqFg

06/05/2026

In a new Virtual Investor "What This Means" segment, Moleculin CEO Walter Klemp gives insight into why the 45-patient enrollment milestone is a critical step toward the trial’s interim data unblinding, which remains on track for mid-2026 and potentially a defining infection point for the Company. Watch here: https://bit.ly/45j8k6r

06/05/2026

Moleculin today announced results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7. Read more: https://bit.ly/4uhLqFg

06/04/2026

Moleculin today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment highlighting the Company's recent 45 subject enrollment milestone in the Phase 2B/3 MIRACLE trial. Watch the full segment here: https://bit.ly/45j8k6r

Did you see our poster at the 2026 Annual Meeting, highlighting the pooled analysis of Annamycin and its cardiac safet...
06/03/2026

Did you see our poster at the 2026 Annual Meeting, highlighting the pooled analysis of Annamycin and its cardiac safety profile at high cumulative anthracycline exposure.

Check out our poster presentation here: https://bit.ly/3Qdhe01

Address

5300 Memorial Drive, Suite 950
Houston, TX
77007

Telephone

+17133005160

Website

Alerts

Be the first to know and let us send you an email when Moleculin Biotech - MBRX posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Moleculin Biotech - MBRX:

Shortcuts

Share

Category